Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2004

View Archived Issues

Selective GABA-A alpha3 receptor subtype agonist and diazepam show comparable effects in vivo

Neurocognitive benefits of methylphenidate in children who survive leukemia or brain tumors

Triage D-Dimer test cleared for use

European MAA submitted for Cubicin

NT-proBNP test cleared for use in two new indications

Buprenorphine analogue inhibits morphine-induced behavioral sensitization in mice

Nonpeptide orally available SK channel blockers for gastrointestinal motility disorders

Orally active cathepsin inhibitor effective against osteoporosis in vivo

Study on effects of RWJ-333369 support use of chronic models in antiepileptic drug discovery

Endovasc reports positive drug delivery findings

PhytoMedical enters CRADA to synthesize type 2 diabetes compounds

FibroGen reports positive findings for oral anemia therapy FG-2216

Fast track status for AMG-531 in immune thrombocytopenic purpura

AMG-706 awarded fast track status

Maxygen announces new development program, reprioritizes pipeline

CytRx investigates two distinct approaches for treatment of ALS

Preclinical studies support the use of MLN-518 in AML

New data on the neurophysiological effects of talampanel in humans

Update on the safety and antiepileptic effects of retigabine

TaiGen claims novel series of chemokine receptor modulators

New benzimidazole derivatives for CNS disorders under study at NeuroSearch

Novartis researchers design new immunosuppressant and antiinflammatory agents

Scientists at Predix report 5-HT2B receptor modulators for CNS and vascular disorders

New compounds acting on melanocortin receptors reported by SCRAS

Gamma-secretase inhibitors identified at Merck

Aryplase submitted for European approval

Clinical responses seen in phase I/II study of Humax-CD20 in NHL

BioVisioN spins off ImVisioN

Medarex and PharmAthene to develop and commercialize MDX-1303

Topline results from phase III study of edifoligide for peripheral bypass graft

LAB International plans phase II study of GHRH analogue

Endovasc plans phase III trial for Liprostin in 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...